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Protein kinases are becoming widely investigated targets for treatment of protozoal parasitic tropical dis-
eases such as malaria and leishmaniasis. The search for potent, selective inhibitors of these parasitic
enzymes has been aided by the extensive variety of structures prepared for human diseases. Genomic
approaches to target identiﬁcation and validation have aided the search. Substantial progress has been
made and research is continuing to expand in an effort to ﬁnd safe, effective drug candidates for these
difﬁcult to treat and widespread diseases.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Targeting protein kinase enzymes is a well-established ap-
proach for the treatment of disease because of the key role these
enzymes play in a variety of cellular processes including cell
division and signal transduction. Signiﬁcant interest is focused on
the discovery of kinase inhibitors for the treatment of human con-
ditions. There is increasing interest in exploring protein kinase tar-
gets for infectious diseases including malaria, leishmaniasis,
tuberculosis and others. Similar to humans, the non-mammalian
kinome encodes a large number of enzymes, with estimates rang-
ing between 80 and 190 kinases that regulate essential processes
including growth, development and reproduction in these organ-
isms.1,2 Since many kinase targets in humans are aimed at the
treatment of neoplastic disease, the question of kinase selectivity
for non-mammalian enzymes is a key issue. Preliminary results
as outlined below and in other studies to date suggest this question
can be adequately addressed because of differences in structure
between the two families of enzymes.3 Structural diversity in
mammalian kinase inhibitor chemotypes provided a rich source
of potential leads/hits for optimization against parasitic kinases.
In addition to these focused libraries, fragment and virtual screen-
ing as well as natural products all provided useful starting points
leading to essential chemical probes for kinase function in the tar-
get organism.
The discovery and optimization of anti-parasitic protein kinase
inhibitors has been reviewed by others.4–6 These summaries pro-
vided an overview of parasitic kinase inhibitor identiﬁcation with
an emphasis on malarial enzyme targets. This review will focus
on reports that have appeared since 2010 with discussion of inhib-
itor optimization and identiﬁcation (primarily in a hit to leadY-NC-ND license.sense) and on recent reports associated with target selection and
hit identiﬁcation.
Kinases associated with Plasmodium falciparum the causative
agent for malaria have attracted signiﬁcant interest in attempts to
treat the disease. The organism has a number of distinct stages in
its lifecycle and a family of calcium dependent protein kinases
(CDPKs) in the parasite that do not exist in eukaryotic cells are
thought to be involved in transitions between one stage and an-
other.7 Onemember of this family, CPDK5was hypothesized to play
a role in erythrocyte egress and/or invasion andwas investigated by
Dvorin and colleagues as a potential drug target.8 Molecular biology
techniques demonstrated that CPDK5 levels could be manipulated
in the mature schizont stage of the life cycle. By deleting the gene
for the kinase from the organism’s genome the group demonstrated
that CDPK5 is essential for movement from erythrocytes. CDPK5-
deﬁcient P. falciparum normally proceeded through other stages
in the life cycle until the late schizont stage. At this writing, no small
molecule inhibitors of CDPK5 have been published.
A related kinase in the same family, CDPK4 was investigated as
a potential target in an attempt to interrupt transmission of the
disease by blocking ex-ﬂagellation of P. falciparum microgametes.9
CDPK4 has a serine residue at the gatekeeper position over the
ATP binding pocket. This comparatively small residue leads to a
noticeably larger ATP binding site compared to nearly all mamma-
lian counterparts, leading to substantially improved kinase selec-
tivity. A compound that was previously studied for inhibition of
other members of this family, BKI-1 (1, Fig. 1) was screened for
kinase inhibition and showed an IC50 of 4 nM. Closely related
derivatives from the same focused library such as 2 had lower po-
tency (IC50 177 nM). The naphthyl moiety in 1 helps to occupy the
larger ATP site and in many cases is too large to be accommodated
by mammalian kinases. In general molecules in this family dem-
onstrated lower potency against mammalian Src and Abl kinases
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Figure 1. CDPK4 inhibitors.
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lian ﬁbroblast cytotoxicity up to 15 lM. When 1 was administered
intraperitoneally (ip) at a dose of 50 mg/kg to Plasmodium berghei
infected mice, exﬂaggelation was completely suppressed for up to
14 h. To evaluate the ability of the compound to prevent disease
transmission from mice to mosquitos, gametocyte-infected mice
that received 10 mg/kg ip completely suppressed formation of
oocysts after allowing the mosquitos to feed for up to 30 minutes.
Infective sporozoites were completely absent from salivary
glands of mosquitos previously fed with human blood containing
3 lM 1.
The role of a cyclic GMP-dependent protein kinase in gameto-
genesis in P. falciparum (PfPKG) was established using a trisubsti-
tuted pyrrole 3 (Fig. 1).10 This ATP competitive inhibitor has an
IC50 of 8 nM against the kinase. Inhibitor 3 prevented the progres-
sion of P. falciparum schizonts through ring stages in an erythrocyte
invasion assay. A strain of P. falciparum with PfPKG modiﬁed to be
insensitive to 3was able to complete schizogeny in the presence of
3 but not in the presence of staurosporine, a broad spectrum kinase
inhibitor that inhibited the mutant enzyme.
Two recent papers highlight phosphoinositide-3-kinase (PI3 K)
as a target of interest. In one report, NVP-BEZ235 (4, Fig. 2) a dual
acting mTOR (mammalian target of rapamycin)-PI3 K inhibitor
was tested in vitro and in vivo against Trypanosoma brucei, Trypan-
osoma cruzi, Leishmania major and Leishmania donovani.11 NVP-
BEZ235 showed IC50 values versus mammalian mTOR and four
PI3 K isoforms (a, b, d, c) less than 10 nM. In culture activity against
the trypanosomids above ranged (IC50) from less than 10 to 140 nM.
In a mouse model of T. brucei infection 4 at an intraperitoneal dose
of 5 or 10 mg/kg administered once daily for four days cleared the
parasite from circulation. Interestingly, 4 was inactive in vivo
against T. cruzi and L. major. One isoform of PI3 K, PI3 Kc appears
to play a central role in phagocyte invasion and disease progression
due to Leishmania mexicana.12 L. mexicana is an obligate intracellu-
lar parasite and PI3 Kc kinase plays a key role in phagocytosis, T cell
recruitment and other processes in leukocytes. Inhibition of the ki-
nase in host cells was hypothesized as a new approach to treat this
parasitic infection. Using the PI3 Kc-selective inhibitor AS-605240N
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Figure 2. PI3 kinase Inhibitors.(5) cell culture and in vivo experiments demonstrated this concept
has potential. When administered 7 weeks after infection with L.
mexicana in the ear, AS-605240 at a dose of 15 mg/kg twice daily
for two weeks was as effective in reducing parasite burden as a
20 mg/kg dose of sodium stibogluconate, a standard treatment for
the disease. Histopathological examination of ear tissue revealed
that AS-605240 treatment produced a reduction in inﬂammation
and parasite inﬁltration comparable to sodium stibogluconate.
A transcriptional cyclin dependent kinase, Pfcrk-3, in P. falcipa-
rum was recently identiﬁed by Doerig and co-workers.13 This ki-
nase localizes with histones in the organism and is found in a
complex with other kinase enzymes. Using genetic techniques
Pfcrk-3 appears to play a role in intra-erythrocyte development
of the parasite. No small molecule inhibitors of this enzyme have
been published to date.
Trivedi and Nag recently carried out an in silico exercise to
characterize PFD0975w, an atypical kinase in P. falciparum as a po-
tential drug target.14 The enzyme is related to RIO-like kinases that
are essential for parasite survival because of their role in the cell
cycle and for ribosome biogenesis. Regions in the protein responsi-
ble for binding ATP and a peptide substrate were identiﬁed. Se-
quence comparison with other RIO kinases enabled development
of a structural model into which sample peptide substrates were
bound. Charged surface residues that could assist or attract sub-
strate proteins were highlighted and potential binding sites inside
the enzyme were identiﬁed that would permit interaction with the
ATP binding site to enable phosphorylation. The authors suggest
that this can be used to enable a virtual screen for inhibitors.
Cyclin dependent kinases (CDKs) were among the ﬁrst non-
mammalian kinases targeted in the search for novel anti-parasitic
agents. In spite of their highly conserved role in cell cycle progres-
sion,15 sufﬁcient differences between eukaryotic and parasitic en-
zymes allow for selective inhibition of non-mammalian
target.16,17 A number of family members in Plasmodium have been
investigated including PFPK5, PFPMK6 and Pfmrk for inhibition by
focused kinase libraries. Waters and co-workers recently identiﬁed
a series of sulfonamides with a broad range of Pfmrk activity
(200 nM–330 lM) and evidence for plasmodial selectivity. For
example, dichlorothiophene sulfonamide 6 (Fig. 3) inhibited Pfmrk
with an IC50 of 600 nM and showed IC50s greater than 20 lM
against human CDKs 1, 2, 6 and 7. Compound 6 was tested against
a range of human cell lines in culture along with a P. falciparum
strain in an attempt to demonstrate cytotoxic selectivity. In culture,
modest anti-malarial activity was seen (IC50 17 lM) and weaker
(45–55 lM) activity against human cancer cell lines. Structurally
related sulfonamides with similar Pfmpk activity gave comparable
results. The authors noted that their results do not provide a direct
correlation between Pfmpk inhibition and anti-malarial activity.
Furthermore they point out that the sensitivity of P. falciparum to-
wards cell cycle kinase inhibition is not known leading to the pos-
sibility that even the comparatively modest inhibition of enzyme(s)
in the pathway could result in parasite death. There is evidence for
structure–activity in this set of compounds as illustrated in the ana-
logs of 6 shown in Figure 3. It is possible the difference in potencyN
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Figure 3. Pfmrk inhibitors.
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6790 D. P. Rotella / Bioorg. Med. Chem. Lett. 22 (2012) 6788–6793between 6 and 8 is due to the relative reactivity of the halo amides
in each molecule. This possibility was not addressed in the Letter.
Given the potentially reactive nature of the bromo/chloroacetamide
moiety, the possibility exists thesemoleculesmay react with nucle-
ophiles in many enzymes and proteins. At this point, no reports
have appeared on in vivo activity with these compounds.
High throughput screening of approximately 40,000 com-
pounds was performed against CRK3 kinase, a cyclin dependent ki-
nase found in Leishmania major.18 CRK3 kinase activity peaks at the
G2/M interface in the parasitic cell cycle and earlier work demon-
strated that inhibition led to cell cycle arrest. The libraries in this
work included kinase inhibitor templates, heterocycles and natural
product mimics. One sub-library in the group was designed based
on a computational approach to target the so called ‘DFG out’ con-
formation of the kinase. A number of structurally related purine
derivatives were identiﬁed with lowmicromolar activity and selec-
tivity for the parasite CDK against the human homolog CDK4 for all
active molecules was limited. Hits were validated by re-synthesis
and re-testing against CRK3 to conﬁrm initial results and selected
compounds were tested in culture against L. major. One molecule,
compound 9 (Fig. 4) demonstrated activity against the promasti-
gote form (parasite with a ﬂagellum) of L. major and was inactive
against amastigotes (an intracellular non-ﬂagellate stage in the life
cycle).
Another high throughput screen was employed to identify
inhibitors of Leishmania CRK3 using an in house library of approx-
imately 3400 kinase inhibitors in an isolated enzyme assay.19 This
yielded a number of chemotypes (e.g., 10–14) as shown in Figure 4.
Additional structure activity exploration was carried out on aryl
derivatives of 12 that signiﬁcantly improved selectivity versus hu-
man CDKs and in some cases improved CRK3 potency (e.g., 15,
Fig. 5). Further modiﬁcations at the amide moiety in benzimidazole
16 and triazole 17 furnished additional potency enhancement and
maintained selectivity. Optimizations were carried out on other
series as well leading to more potent derivatives. A number of
compounds were tested in cell culture for activity against wild
type promastigote L. major and only a single molecule, 17, showed
measurable activity (data not shown). Given the close structural
similarity between 16 and 17, this observation raises questions
regarding the mechanism(s) resulting in anti-parasitic activity.
Possible explanations for this observation were not provided by
the authors and raise the possibility that these molecules exert
their activity against an unidentiﬁed target(s) in the organism.N
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Figure 4. CRK3 iA virtual screen of over 45,000 compounds was carried out
aimed at identifying inhibitors of Toxoplasma gondii kinase
ROP18.20 This secreted parasitic kinase is directly implicated in dis-
ease outcome and crystal structures of other members of the
superfamily are available. This screen for ATP-competitive mole-
cules identiﬁed 17 potential hits that were tested against T. gondii
in culture. Assays for ROP18 inhibition were not carried out. Based
on the IC50 for growth inhibition (2 nM) for one of these hits, 18
(Fig. 5), and low level of ROP18 expression in the T. gondii strain
that was used, the authors hypothesize that ROP18 is not the pri-
mary molecular target. Compound 18 and analogs showed no evi-
dence of human cell cytotoxicity in culture and at a concentration
of 2 lM destroyed parasite containing vacuoles. The molecular tar-
get(s) for this series of compounds is not known, however these re-
sults suggest there is some promise in the series that justiﬁes an
attempt to identify the possibilities.
In an attempt to identify novel compounds active against Try-
panosoma brucei, the causative agent in African trypanosomiasis
(sleeping sickness), a library of 2,4-diaminopyrimidines was evalu-
ated in a phenotypic screen.21 Hits were then optimized leading to
the identiﬁcation of SCYX-5070 (19, Fig. 6). This molecule demon-
strated rapid, potent parasitotoxic effects in cell culture with an
IC50 value of 70 nM against procyclic and blood stage T. brucei and
1–2 lM against promastigote and amastigote forms of L. donovani.
When administered post infection with T. brucei orally or by intra-
peritoneal injection at a dose of 20 mg/kg twice daily for 4 days aN N
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Figure 6. Diaminopyridimidine kinase inhibitors.
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toxicity.
Given these promising results, it was essential to attempt to
identify molecular target(s) for SCYX-5070. Towards this end
derivative 20 was immobilized via the phenolic hydroxyl group
on a solid support and exposed to T. brucei and L. major cell lysates.
Proteins that bound to the matrix were identiﬁed using MALDI-TOF
LCMS analysis and tryptic digestion. Kinases in the CRK and MAPK
family were well represented in the group. MAPKs 2 and 9 in both
organisms, CRK1 and 6 from T. brucei and CRK3 in the L. major
lysate were among the most notable drug binding proteins. This
paper did not provide isolated enzyme inhibition data or an evalu-
ation of target versus mammalian kinase selectivity. However,
literature evidence was cited to suggest that related 2,4 diamino-
pyrimidines can demonstrate selectivity for parasitic kinases
compared to human homologs.
Maly and co-workers investigated the observation by Shokat
and colleagues that the gate keeper residue in kinase enzymes
can play a critical role in determining selectivity.22 In parasitic
CDPKs glycine occupies this key site leading to a larger ATP binding
pocket, while many mammalian enzymes have valine, threonine or
serine at this position.23 Their initial work focused on 4-aminopy-
razolopyrimidines related to 1. Attention was focused on N1 and
C3 substituents on the scaffold (Fig. 7). SAR analysis revealed that
certain naphthyl regioisomers or derivatives thereof were preferred
at C3 and that small hydrophobic or unsubstituted piperidines for
example, 21a–cwere favorable for activity. More detailed structure
activity studies of substituted pyrazolopyrimdines in this series
against the apicomplexan calcium dependent kinase CDPK1 found
in T. gondii were carried out by the same group.24 In this study, a
wide range of aromatic C3 substituents were investigated along
with aliphatic and cyclic amines attached at N1 of the template.
Compound design and optimization was aided by analysis of avail-
able crystal structures of enzyme–inhibitor complexes. The basic
design hypothesis that a large binding pocket in the native CDPK1
would accommodate bulkier C3 substituents was validated byN
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Figure 7. CDPKcomparison of wild type inhibition data with a mutant form where
glycine was replaced by methionine. In each case, compounds with
potent wild type CPDPK inhibition proved to be weak (>3 lM)
against the methionine-containing enzyme. A number of molecules
(22a–c) demonstrated potent T. gondii growth inhibition in culture
as illustrated in Figure 7. Depending on the molecule and enzyme,
selectivity versus mammalian kinases ranged from 10-fold versus
LCK to greater than 1000-fold for p38a. None of these T. gondii
CDPK1 inhibitors prevented human cell growth up to 10 lM in
culture.
This group extended structure activity investigations in this ser-
ies to improve CDPK selectivity based on conformational analysis
of selective molecules such as 22c.25 The piperidinylmethyl moiety
at the R1 position (Fig. 7) occupies the ribose pocket in the enzyme
and takes advantage of speciﬁc interactions in this region to rein-
force selectivity for the parasitic kinase. To take advantage of this,
an acyl benzimidazole template 23 (Tg CDPK1 Ki 340 nM, Fig. 8)
was modiﬁed to occupy the ribose pocket leading to 24, with a Ki
value of 7.5 nM and excellent selectivity versus SRC and ABL ki-
nase. In these analogs, the piperidine moiety makes hydrogen
bonds with a key glutamic acid residue in the parasitic kinase. A
serine residue occupies the analogous position in SRC and ABL ki-
nase leading to disfavorable enzyme-inhibitor interaction and re-
duced afﬁnity.
This aminobenzimidazole scaffold was investigated in more de-
tail in a recent publication to determine optimal substituents on
the 2-amino moiety and benzimidazole nitrogen.26 The ketone
moiety was essential for inhibition as demonstrated by inactive
racemic alcohol 25 (Fig. 8). Analysis of the available crystal struc-
ture data suggested the 2-amino substituent projected into a
hydrophilic region on TgCDPK1 and although a variety of groups
were tolerated and several led to more potent derivatives, substi-
tution at this locus did not improve kinase selectivity and in many
cases resulted in less speciﬁc inhibitors. Using an ethyl amino
amide derivative, a variety of cyclic amine substitutions at R1
(26, Fig. 8) provided potent and selective CDPK1 inhibitors withN
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low mammalian cell cytotoxicity and unfortunately no activity in
T. gondii or C. parvum cell culture assays. The authors speculate this
could be due to poor parasite cell penetration or export by molec-
ular pumps.
In the search for kinase inhibitors with the potential to treat
tuberculosis, researchers at the Southern Research Institute con-
ducted a high throughput screen using a focused kinase library.27
This work was carried out as a component of a broad based effort
by the Tuberculosis Antimicrobial Acquisition and Coordinating
Facility to identify chemically tractable leads. The library was com-
posed of over 25,000 compounds that included broad spectrum
and targeted kinase templates. Samples with potentially problem-
atic functional groups such as aromatic nitro compounds were ex-
cluded, as were samples whose Lipinski characteristics were
outside guidelines. As an additional ﬁlter, compounds were in-
tended to target the ATP binding pocket and were required to pos-
sess a typical hinge binding pharmacophore that included two
hydrophobic regions with hydrogen bond donors and acceptors
as a part of the structure. The screen was conducted using the
H37Rv strain ofMycobacterium tuberculosis rather than a mycobac-
terial kinase inhibition assay to provide an IC90 value for inhibition
of bacillus growth. This value was compared to Vero cell cytotox-
icity and a selectivity ratio of at least 10 was needed for more de-
tailed study.
A number of scaffolds were identiﬁed with good anti-tubercular
activity and acceptable selectivity. Among these, the examples
shown in Figure 9 are representative of the templates with hitsN
N
N
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cytotoxic selectivity > 28
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H3CO
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Figure 9. Antitubercular kin the library. In each case, several examples were identiﬁed and
validated that had potency, selectivity (based on cytotoxicity)
and structural novelty as potential kinase inhibitors. The initial
data provided some structure–activity information coupled with
antitubercular properties. 1,2,3-Benzotriazinone 27 is an unusual
kinase template because of the lack of a hydrogen bond donor. This
molecule had an IC90 value of 1.4 lg/mL and showed greater than
28-fold selectivity in a cytotoxicity screen. The more well-known
pyrazolopyrimidine nucleus was identiﬁed and exempliﬁed by 28
with an IC90 of 1.7 lg/mL and 19-fold selectivity. The largest group
of hits were based on a 1,3,4-oxadiazole core 29. In this group, a
sufﬁcient number of examples were evaluated to guide prelimin-
ary structure activity studies. For example, an aryl moiety at R1
was optimally a heterocycle such as a pyridine. Phenyl rings at this
position were generally much less active or inactive. A broader
range of substituents at R2 were tolerable including alkyl, aryl, het-
eroaryl and poly aromatic groups. In this scaffold more than half of
the hits were deﬁned as non-toxic using a selectivity index of 15 as
the lower limit. Like some of the HTS screens carried out versus
other parasites (vide supra), no direct kinase inhibition assays were
carried out and no speciﬁc kinases were targeted or hypothesized
by the investigators.
The ﬁeld of kinase inhibitor discovery for treatment of parasitic
diseases is accelerating as a variety of leads, hit scaffolds and en-
zymes are identiﬁed. The existence of a large number of kinase li-
braries designed to inhibit mammalian targets provides a wealth of
information that is being applied to the optimization of parasitic
kinase inhibitors. Researchers have used these starting points to
improve the potency and speciﬁcity for target enzymes. As readers
compare the structures and leads highlighted in this review with
those identiﬁed in other recent summaries, note the expanded
chemical diversity in last two years and the additional enzyme tar-
gets that have been identiﬁed. Experience in the form of SAR data
and crystal structures revealed that signiﬁcant differences exist be-
tween the ATP binding sites of several parasitic enzymes, relative
to their human homologs. These distinctions permit measurable
and sometimes substantial differences in selectivity allowing ad-
vanced testing of candidates in pre-clinical disease models. Pro-
gress in this regard is noteworthy as well, exempliﬁed by the
‘bumped’ inhibitors being investigated by Ojo, and Murphy and
colleagues.
Investigators in the ﬁeld are using the now well established
tools of genomics, virtual screening and structure based drug
design to develop potent, drug like leads for investigation. ByN N
OR1
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N
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D. P. Rotella / Bioorg. Med. Chem. Lett. 22 (2012) 6788–6793 6793applying contemporary guidelines for drug like compound proper-
ties, researchers in the ﬁeld are using the lessons learned in the hu-
man kinase inhibitor realm to deliver high quality compounds for
clinical study in the treatment of these serious and widespread dis-
eases. While clinical candidates are not yet in hand, this may
change shortly due to the attention being devoted to this extre-
mely important world health issue. Patients and clinicians can then
look forward to effective treatments that will reduce mortality and
improve the quality of life for those afﬂicted by these serious
infections.
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